Location History:
- Littleton, MA (US) (2022)
- Reading, MA (US) (1999 - 2023)
Company Filing History:
Years Active: 1999-2025
Title: Mark R. Jones: Innovator in Particle Therapy Systems
Introduction: Mark R. Jones, an accomplished inventor based in Reading, MA, holds a remarkable 22 patents in the field of particle therapy systems. His innovative contributions significantly enhance the precision and effectiveness of treatments, showcasing his dedication to advancing medical technology.
Latest Patents: Among his latest patents, Jones has developed a "Gantry for a Particle Therapy System." This invention features a gantry equipped with a beamline structure designed to direct a monoenergetic particle beam from a particle accelerator towards a specific irradiation target. The beamline includes magnetic bending elements that strategically bend the particle beam, while an energy degrader, located downstream, is configurable to alter the particle beam’s energy before it reaches the target. Additionally, Jones has patented a "Treatment Planning" method, which involves receiving dose distribution information for an irradiation target and performing operations that adjust the particle beam to optimize treatment efficacy.
Career Highlights: Throughout his career, Mark R. Jones has made significant strides in the medical technology sector. He has worked with reputable companies such as Mevion Medical Systems, Inc. and Affymetrix, Inc., where he has played a pivotal role in the development of innovative solutions that enhance therapeutic techniques.
Collaborations: Jones has collaborated with notable colleagues, including James Cooley and Gerrit Townsend Zwart. Their teamwork has facilitated advances in the field, contributing to enhanced patient care and treatment outcomes.
Conclusion: Mark R. Jones stands out as a visionary inventor whose work in particle therapy systems demonstrates a profound commitment to innovation in medical technology. His patents not only reflect his expertise but also signify meaningful advancements in cancer treatment approaches, making him a key figure in the evolution of therapeutic systems.